Project Grant P01AI202802
Award Date 9/1/26
Completion Date 7/31/31
Dollars Obligated $4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $805,253 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms underlying airborne transmission of seasonal influenza A viruses, specifically H1N1 and H3N2 subtypes. The recipient will characterize aerosol particle size distributions and virion morphologies of H1N1 and H3N2 using samples from human patients, laboratory-generated...
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $2.767 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the NFKB signaling network in the regulation of resident T cell memory. The research addresses how tissue-resident memory T cells (TRM) are generated and maintained in the lungs following infection. While CD8 TRM cells in multiple tissues provide superior protection against...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.959 million on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the Michigan Influenza Transmission Research Center's observational studies of human influenza transmission. The award funds three coordinated research projects examining influenza transmission through the epidemiologic triangle framework of pathogen, host, and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Washington University $765,798 on September 3, 2026, to develop a mucosal H5 influenza virus vaccine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop a single-dose mucosal vaccine using a chimpanzee adenovirus vectored platform to confer robust protection against high-dose H5N1 challenge and transmission in pre-clinical...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $149,190 to the University of Massachusetts Medical School on December 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project grant (F31AI191745) to investigate hemagglutinin-mediated molecular mechanisms of avian influenza A virus host tropism. The research examines how the hemagglutinin (HA)...
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $538,501 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize RNA aptamer tools for studying HIV capsid protein structural dynamics and function. The award funds research to develop novel aptamers capable of discriminating among distinct structural forms of HIV's CA protein, which plays critical roles in viral assembly,...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of the University of Pennsylvania $3.16 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune imprinting and cross-reactive antibody responses to pandemic influenza viruses. The research examines how childhood exposure to seasonal influenza viruses creates long-lived immunological imprints that may provide protection against novel pandemic...